Oncotarget’s Vision: When Information Needs to be Shared

Oncology is, in basic explanation, the study of cancer and tumors and their effects in the human body and mind. It is a very new, different and crucial part of the medicine that we know today, and scientists all over the world are joining in to study this new sector that is promising to take care of one of the deadliest and most terrifying diseases in the world, with thousands of different types.

Cancer has evolved to be a very present disease in our society, and many don’t understand how cancer attacks, what makes someone get cancer and why do people that do not take care of their health end up unchecked, while those who exercise and eat well can often be the next targets for that disease. The truth is, many of the characteristics that we know about cancer today have just been recently discovered, with just a few years of research to back those findings up, and, often, it is not enough. Follow Oncotarget on Twitter.

Because of the scarcity of information that this new field of medicine can provide, scientists and researchers, as well as those who feel the importance of knowing about the disease, have to gather around and share knowledge with each other.

This is where websites that spread the news about oncology, and the same goes for the other sectors of medicine as well, are so important for the progress of those studies. Oncotarget is our primary choice for example, as it is a peer-reviewed website with articles that are 100% free to read, share, use, learn, and, of course, put in practice. Learn more about Oncotarget at Eurekalert.org.

Oncotarget was created with the purpose of, every week, sharing news about the oncology world, but, with the fame that it received, and the number of people that began using the website to learn more about the most recent findings about the disease, the website started increasing their publication-rate and the number of articles that they publish.

Today, Oncotarget is the most famous website for that function, and they have other branches that touch other subjects other than oncology, with many different types of research in mind. If you need to know more about the disease, take a look at Oncotarget.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Clay Siegall: Finding Alternatives to Cancer Treatment

Clay Siegall has been influential in finding alternative treatments to cancer. He is a successful entrepreneur who has adopted technology in establishing a drug manufacturing company and providing technologies and processes for cancer care and therapies. He has a passion for helping others and believes in proving patients with drugs that would alleviate their pain and help them live a better life.

Clay Siegall spoke to Inspirery on his desire to reduce the effects of chemotherapy on patients, which motivated him to pursue cancer care and treatment by conducting research on alternative drugs. He talked about his vision of incorporating technology to medicine to provide better treatments that are efficient and effective. Dr. Siegall is the co-founder of Seattle Genetics, which manufacturer drugs to aid in relief of cancer suffering in patients. He explains that the company makes its revenue through sale of the drugs and licensing technologies and processes it develops. These are all geared towards providing therapeutic cure.

Dr. Clay Siegall has conducted extensive research in cancer. He has spent his postgraduate years working in drug manufacturing companies where he held various positions in research. Siegall graduated from Maryland University with a BS in Zoology. He developed an interest for cancer as a student having experienced the agony of a sick relative. He was curious and determined to find ways of lessening the burden of cancer hence proceeded to undertake a PhD in genetics at George Washington University.

Dr. Siegall started his postdoctoral work as a senior research investigator at Bristol-Myers Squibb Pharmaceutical Research Institute. He acquired great skills and expertise in conducting research and was able to research on cancer. Siegall has spent over twenty years researching on cancer treatments and drugs. His dedication and hard work towards achieving his vision are unmatched and recognized. He also served as a principal scientist at Bristol-Myers.

At Seattle Genetics, Siegall serves at various positions that include chair of the board, the president, and its chief executive officer. He carries out his roles with great diligence and is committed to ensuring the success of the company as a cancer centre.